Mode
Text Size
Log in / Sign up
N/A N=20 Basic Science

Poor Sleep and Inflammation in HIV-Infected Adults

HIV-1-infection · Sleep Deprivation · Inflammation

Enrolled (actual)
20
Serious AEs
0.0%
Results posted
Oct 2023
Primary outcome: Primary: Soluble CD14 — 1290; 1196 ng/mL

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Sleep deprivation (Behavioral)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
University of Pittsburgh
Primary completion
Jul 2022

Outcome Measures

OutcomeResultp-value
PRIMARY
Soluble CD14
1290; 1196
PRIMARY
Soluble CD163
359; 384
PRIMARY
IL6
4.46; 4.27
SECONDARY
Flow Mediated Brachial Artery Dilation
6.13; 4.42
SECONDARY
Monocyte Expression of IL6
84.6; 89.1
SECONDARY
Monocyte Expression of TNF-alpha
52.0; 64.1
SECONDARY
CD4+ T-cell Expression of HLA-DR and CD38
8.14; 8.39
SECONDARY
CD8+ T-cell Expression of HLA-DR and CD38
12.30; 13.17

Summary

People living with HIV (PLWH) often have poor sleep, which may put them at a higher risk for many chronic diseases, including cardiovascular disease. One of the mechanisms by which this may occur is via chronic inflammation and endothelial dysfunction. Adenosine plays an important role in sleep homeostasis, with levels increasing in the CSF in response to sleep deprivation and falling with sleep. Peripherally, adenosine, via its signaling pathway, plays an important role in immunoregulation by suppressing the inflammatory response. PLWH, even on antiretroviral therapy, have suppressed peripheral adenosine levels which are predictive of adverse cardiovascular outcomes. The hypothesis underlying this study is that acute sleep deprivation in PLWH does not result in a compensatory increase in extracellular adenosine and its signaling peripherally, and this failure to appropriately compensate, leads to an increase in systemic inflammation and endothelial dysfunction.

Eligibility Criteria

Inclusion Criteria

  • HIV positive
  • On continuous anti-retroviral therapy regimen for at least 48 weeks
  • CD4+ cell count greater than or equal to 200 cells/mm^3

Exclusion Criteria

  • Irregular or insufficient habitual sleep patterns
  • Severe advanced or delayed sleep phase
  • Primary sleep disorder
  • Autoimmune disorder
  • Use of immunosuppressant medications
  • Use of medications impacting adenosine pathway
  • Heavy caffeine use
  • Active alcohol or drug abuse
  • Elevated risk of adverse health effects from sleep deprivation (e.g., bipolar disorder, epilepsy, or suicidal ideation in the past 6 months)
  • Pregnancy
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03848325). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search